Clinical Trial Update: Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating lapatinib for advanced or metastatic HER2-overexpressing breast cancer has been completed. The trial was sponsored by the University …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Breast Cancer, Metastatic Cancer | Phase 1 | Status: COMPLETED